Share this Search Print Search Results Keyword Search Location Distance 10 mi (16 km) 50 mi (80 km) 100 mi (160 km) 150 mi (241 km) 200 mi (321 km) 300 mi (483 km) 400 mi (644 km) 500 mi (805 km) This trial finder is only for Seagen trials. You may also be eligible for other clinical trials. You can find information on other clinical trials at www.clinicaltrials.gov. Refine Search Applied Filters 0 Clear Filters Patients and Caregivers Healthcare Professionals Site Map Contact Us FAQs Sign up for updates This website is intended for U.S. residents only. ©2021 Seagen Inc. Privacy Policy Terms and Conditions Social Media Terms Cookie Notification By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our Cookies Policy. Accept

Search Brentuximab vedotin Explore Ongoing Studies See How It Works Brentuximab vedotin (ADCETRIS®) targets CD30 using our proprietary antibody–drug conjugate (ADC) technology. CD30 is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma, but not commonly found on healthy cells. This ADC therapy uses a linker system that is designed to be stable in the bloodstream and release a cytotoxic (cell-killing) agent once internalized into CD30-expressing cells, resulting in targeted cell death. Brentuximab vedotin is composed of an anti-CD30 monoclonal antibody and a cytotoxic agent, monomethyl auristatin E (MMAE), which are attached by a protease-cleavable linker. Brentuximab vedotin is being developed in collaboration with Takeda Pharmaceutical Company. Proposed mechanism of action of brentuximab vedotin and nivolumab View Details This proposed mechanism is based on nonclinical data. Brentuximab vedotin is an investigational agent in this setting. Its safety and efficacy have not yet been established. References + Patients and Caregivers Diseases We Study Real Stories Clinical Trials Support and Resources Healthcare Professionals Medical Information Clinical Data Requests Investigator-Sponsored Research Medical Education Grants Site Map Contact Us FAQs Sign up for updates This website is intended for U.S. residents only. ©2021 Seagen Inc. Privacy Policy Terms and Conditions Social Media Terms > Cookie Notification By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our Cookies Policy. Accept